REVIEW ARTICLE published: 14 October 2010 doi: 10.3389/fphar.2010.00116 PG F2α receptor: a promising therapeutic target for cardiovascular disease Jian Zhang, Yanjun Gong and Ying Yu* Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Graduate School of the Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China Edited by: Prostaglandins (PGs), a group of key lipid mediators, are involved in numerous physiological Colin D. Funk, Queen’s University, and pathological processes including inflammation and cardiovascular homeostasis. Each PG Canada acts on its specific and distinct cell surface G protein-coupled receptors (GPCRs) or peroxisome Reviewed by: proliferator-activated receptors (PPARs). Prostaglandin F receptor (FP) is required for female Aida Habib, American University of 2α Beirut, Lebanon reproductive function such as luteolysis and parturition. It has recently been implicated in blood Duxin Sun, University of Michigan, pressure regulation, atherosclerosis and other inflammation-related disorders. The emerging USA role of FP in cardiovascular diseases is highlighted and potential therapeutic translation is *Correspondence: discussed in the current review. Ying Yu, Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Keywords: prostaglandin F2alpha, hypertension, atherosclerosis, FP receptor Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Graduate School of the Chinese Academy of Sciences, 294 Tai Yuan Road, Shanghai 200031, China. email:
[email protected] INTRODUCTION through peroxidase activity (POX) of PGHS enzymes. Subsequently Prostanoids, including prostaglandin (PG) E2, PGD2, prostacy- the PGH2 is subject to metabolize to active prostanoids through clin (PGI2), thromboxane A2 (TxA2), and PGF2α, are generated individual PG synthases (Figure 1).